Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Novartis
Enliven Therapeutics
Novartis
City of Hope Medical Center
Shenzhen TargetRx Co., Ltd.
Augusta University
Takeda
University of California, Irvine
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
City of Hope Medical Center
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
Terns, Inc.
City of Hope Medical Center
City of Hope Medical Center
M.D. Anderson Cancer Center
Children's Oncology Group
OHSU Knight Cancer Institute
City of Hope Medical Center
Medical College of Wisconsin
Barbara Ann Karmanos Cancer Institute
Gruppo Italiano Malattie EMatologiche dell'Adulto
Roswell Park Cancer Institute
Enliven Therapeutics
UNC Lineberger Comprehensive Cancer Center
City of Hope Medical Center
Ascentage Pharma Group Inc.
Thomas Jefferson University
Fred Hutchinson Cancer Center
City of Hope Medical Center
Ascentage Pharma Group Inc.
Fundacion CRIS de Investigación para Vencer el Cáncer
Il-Yang Pharm. Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
City of Hope Medical Center
City of Hope Medical Center
City of Hope Medical Center
OHSU Knight Cancer Institute
Imperial College Healthcare NHS Trust
University of Nebraska
M.D. Anderson Cancer Center
Hikma Pharmaceuticals LLC
GWT-TUD GmbH
University of Nebraska
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
University of California, San Francisco
UNC Lineberger Comprehensive Cancer Center